Increased matrix metalloproteinases expression in tuberous sclerosis complex: modulation by microRNA 146a and 147b in...

Area of Science:

• Neuroscience
• Biochemistry
• Molecular Biology

Background:

• Matrix metalloproteinases (MMPs) and tissue inhibitors (TIMPs) regulate brain extracellular matrix (ECM) proteolysis.
• MMP/TIMP system dysfunction, driven by neuroinflammation, can compromise the blood-brain barrier (BBB) and contribute to epilepsy pathogenesis.
• This proteolytic system's role in the human epileptogenic brain, particularly in Tuberous Sclerosis Complex (TSC), remains understudied.

Purpose of the Study:

• To investigate the expression and cellular localization of key MMPs and TIMPs in TSC-associated epilepsy.
• To examine the potential of anti-inflammatory microRNAs (miRNAs), specifically miR146a and miR147b, to modulate MMP and TIMP expression in TSC.
• To correlate MMP/TIMP dysregulation with BBB dysfunction in TSC.

Main Methods:

• Quantitative real-time polymerase chain reaction (RT-PCR) and immunohistochemistry were used to analyze MMPs (MMP2, MMP3, MMP9, MMP14) and TIMPs (TIMP1, TIMP2, TIMP3, TIMP4) in resected TSC brain tissue.
• Cellular localization was determined in dysmorphic neurons, giant cells, and reactive astrocytes.
• In vitro studies utilized TSC tuber-derived astroglial cultures to assess the impact of miR146a and miR147b on IL-1β-induced MMP/TIMP dysregulation.

Main Results:

• Elevated mRNA and protein levels of MMPs and TIMPs were observed in TSC tubers compared to control and perituberal tissues.
• Increased expression of MMPs and TIMPs was localized to dysmorphic neurons, giant cells, and reactive astrocytes, correlating with BBB dysfunction.
• miR146a and miR147b successfully rescued IL-1β-induced dysregulation of MMP3, TIMP2, TIMP3, and TIMP4 in TSC astroglial cultures.

Conclusions:

• The MMP/TIMP proteolytic system is dysregulated in TSC, contributing to BBB dysfunction.
• The findings suggest that miR146a and miR147b hold promise as a novel therapeutic strategy for TSC-related epilepsy by ameliorating MMP/TIMP dysregulation.